EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Aggressive Thyroid Carcinomas Clinical and Molecular Features: A Systematic Review

Sorina Schipor, Mihai Alin Publik iD, Dana Manda, Mihail Ceausu iD

International Journal of Molecular Sciences · 10.06.2025 · 26 (12) · 5535

DOI: 10.3390/ijms26125535 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 10.06.2025. Verfasst von Sorina Schipor und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research, "C.I. Parhon" National Institute of Endocrinology, 011863 Bucharest, Romania. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Research, Innovation and Digitization, CCCDI-UEFISCDI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aggressive thyroid carcinomas are rare malignancies characterized by a high impact on patient’s lives and poor prognosis. The available literature is scarce presenting divergent data concerning the clinical outcomes, prognostic factors and variable mutational signature studies. We aim to collect data from the literature and assemble a systematic review. The literature from 2007 until May 2025 was searched using PubMed. Studies bearing data concerning clinical aspects, prognostic outcomes, or molecular characteristics of differentiated high-grade (DHGTC), poorly differentiated (PDTC), and anaplastic thyroid carcinomas (ATC) were retrieved. Original articles in English, ethically conducted on human patients, were selected. From 688 articles, 39 were included. DHGTC has a good 5-year survival rate (5YSR) of 76%, 23.18% metastasis rate, 42.23%, lymph node involvement (LNI), 61.44% extrathyroidal extension (ETE), majority being diagnosed in stage III. PDTC has an intermediate 5YSR of 65.71%, 21.17% distant metastasis, 32.22% LNI, and 55.19% ETE, majority diagnosed in stage III. ATC has a grim 2-year survival rate of 11.15%, 42.15% metastasis, 44.14%, LNI, and 58.51% ETE, majority presented in stage IV-B. Mutational profiling shows that each carcinoma has its unique set of molecular alterations. Most positive prognostic comes for DHGTC, then PDTC, and finally, ATC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsThyroid Carcinoma, AnaplasticHumansPrognosisMutationBiomarkers, Tumor

Stichwörter der Autor:innen

ATCDHGTCPDTCaggressiveanaplasticdifferentiated high gradepoorly differentiatedthyroid carcinoma

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Research, "C.I. Parhon" National Institute of Endocrinology, 011863 Bucharest, Romania.
  • Department of Pathology, "C.I. Parhon" National Institute of Endocrinology, 011863 Bucharest, Romania.
  • Department of Pathology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.

ORCID-Profile: Mihai Alin Publik, Mihail Ceausu

Förderung

  • Ministry of Research, Innovation and Digitization, CCCDI-UEFISCDI

Zitieren

APA

Schipor, S., Publik, M. A., Manda, D., & Ceausu, M. (2025). Aggressive Thyroid Carcinomas Clinical and Molecular Features: A Systematic Review. International Journal of Molecular Sciences, 26(12), 5535. https://doi.org/10.3390/ijms26125535

Vancouver

Schipor S, Publik MA, Manda D, Ceausu M. Aggressive Thyroid Carcinomas Clinical and Molecular Features: A Systematic Review. International Journal of Molecular Sciences. 2025;26(12):5535. doi:10.3390/ijms26125535

BibTeX
@article{Schipor2025,
  author = {Schipor, Sorina and Publik, Mihai Alin and Manda, Dana and Ceausu, Mihail},
  title = {Aggressive Thyroid Carcinomas Clinical and Molecular Features: A Systematic Review},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {12},
  pages = {5535},
  doi = {10.3390/ijms26125535}
}
Kostenlos starten →